The synthetic biology company has developed a DNA synthesis platform that it says enables the industrialization of biology engineering. The core of the platform provides a method of making synthetic DNA by “writing” it on a silicon chip. It plans to develop products like synthetic genes, tools for next-gen sample preparation and antibody libraries for drug discovery and development.
2018 Financials (9 mo.)($M): Revenues: 17.0 (+133.1%); Operating Expenses: 67.9 (+38.0%); Net Loss: (51.4) (-21.5%); Cash Consumption: (49.5) (-24.4%).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.